A laboratory is a place where results are produced, written down and handed to other people to check. That is the whole value of the word, and it is borrowed here by a trading brand that publishes no results at all. Our reading of Slide +Lab Codrix begins with that borrowing, because a reader who accepts it has already granted the service a credibility that nothing in the record supports.
How does Slide +Lab Codrix describe itself?
Promotional material presents the brand as trading software developed through testing and offered to users who register and fund an account. The account of the product is the seller's own and is reproduced here as such.
Pros
- The promotion commits to a clear product category rather than presenting itself as a broker or an adviser
- Sign-up is described as requiring little technical knowledge, which the copy frames as a benefit
The points above summarise what the operator says about its own platform. We have not verified them.
Cons
- A research vocabulary is used without a single published result to support it
- No identified firm stands behind the claims, so no one can be asked to substantiate them
- Terms covering money in and money out are not available to read before registration
The filing
The brand arrived on this docket as an automated trading offer aimed at people without professional experience. What we file is narrow by design: the claim in the seller's own words, the outcome of checks against public sources, the date those checks ran, and the list of questions still open. We publish the unfinished parts because the unfinished parts are the ones that cost readers money.
We do not attempt to judge whether the software works. That would require access nobody outside the operator has. What can be judged from outside is whether the business is identifiable, supervised and answerable, and that judgement is available to any reader willing to spend twenty minutes in a register.
Exhibit A: the platform in its own words
According to its own promotion, the service is trading software refined through testing and made available to anyone who registers and funds an account. The pitch leans on the impression of engineering discipline: something built carefully, measured, improved.
Read that back slowly and the sentence dissolves. Refined against what data, over which period, measured on which benchmark, compared with which alternative? None of those questions has an answer in the material. A claim of testing that omits the method is not a weak claim, it is an unfalsifiable one, and an unfalsifiable claim is the most dangerous kind to accept from a party you cannot name.
There is one part of the copy we take at face value, because it costs the seller nothing to say and happens to be true of the category: the product sold is software, not advice. That distinction usually keeps the operator outside the activities a supervisor licenses, which is convenient for the operator and consequential for the user.
Exhibit B: what the public record returned
Our checks run in a fixed order. First, look for a legal name in the documents that are supposed to carry one: terms of use, privacy notice, footer, registration screen. Second, take that name to the company register of the country claimed. Third, take it to the financial regulator of that country and look for a permission matching the advertised activity. Fourth, search the published warning lists.
The sequence stopped at the first step. No entity name appeared anywhere we looked, which left nothing to carry into the registers. We recorded that outcome rather than substituting a guess, and we date it so that a later reader knows exactly how old the finding is.
We also searched for the brand name itself in warning lists, since supervisors sometimes publish brand names rather than company names. As of the date on this file we found no entry. That sentence should be read as narrowly as it is written: it describes our search, not the platform's standing.
Not in evidence
The following remain unestablished and should be treated as open questions by anyone considering this service: the operating company and its registration number, the country whose law governs the contract, any licence in a supervisory database, the individuals responsible for the business, the payment institution receiving funds, whether client money is separated from company money, the fee structure, and any testing behind the research language in the promotion.
The counterparty question
Money that leaves a bank account for a trading platform stops being protected by the bank and starts depending on the firm that received it. If that firm is supervised, rules generally require client funds to be kept apart from the firm's own resources, and a supervisor exists to enforce them. If the firm is unidentified, none of that applies in any practical sense.
There is also a quieter risk in the payment route itself. Deposits to services of this kind sometimes travel through processors with no obvious connection to the brand, which complicates any later attempt to trace the money or to raise a dispute with a card issuer. A user cannot evaluate that path before depositing unless the platform describes it, and here it does not.
Tests a reader can run without us
Ask in writing for the company name, number and country before you register, and keep the reply. Search the company register of that country for an exact match and check the company is active. Search the regulator's database for a permission held by that exact entity, covering that exact activity. Run both the company name and the brand name through the warning lists at the foot of this page. Then read the withdrawal conditions and save a dated copy.
Risk that belongs to the instrument
Leveraged trading is risky when the provider is fully identified and supervised, and this file should not be read as implying that identification alone would make it safe. Borrowed exposure amplifies losses as readily as gains, positions can be liquidated automatically, and costs accumulate with every trade an automated system opens.
The research framing makes this worse rather than better, because it encourages a reader to believe the risk has been engineered away by someone else's testing. No test result has been published here, so there is nothing to place against the ordinary probability of loss.
Status of the case
Open, unidentified, at the date of the last check above. The file will be rewritten if an operating company is disclosed and found in a register, or if published testing appears that a reader can examine, or if a supervisor names the brand in a document we can cite. Until one of those occurs, the correct summary of this case is the one printed in the verdict box and nothing stronger.
Questions on the docket
Does Slide +Lab Codrix publish any test results?
We found none. A laboratory claim in finance would normally come with a method, a sample period and a result that someone else can reproduce. Where none of that is offered, the word is branding rather than evidence.
Is the brand authorised anywhere?
We could not check, because authorisation is granted to companies and no company is named. A register search needs a legal name, and the material a visitor sees does not provide one.
Is Slide +Lab Codrix connected to other brands with similar names?
We cannot say. Similar name endings appear on other files in this docket, but a shared word is not proof of a shared operator, and the operators are precisely what none of these brands disclose.
What is the minimum I should know before depositing?
The legal name of the firm taking the money, the country that supervises it, the permission it holds, and the written conditions for getting funds back. If a service cannot supply all four before you register, you are being asked to pay for the right to find out later.